Multiple Myeloma

Adding to the Therapy Arsenal

Jack Aiello enthusiastically discusses the additions of newer medicines that were FDA approved in 2015, and why patients need to be aware of them.
Video Library – February 5, 2016
Jack Aiello
Patient Advocate
San Jose, CA
Multiple myeloma survivor

I've been diagnosed 21 years with myeloma and there's never been a more exciting year than 2015. We had a drug approved earlier in February, panobinostat, and then three in November. You're right Sam, that there have been an incredible number of new drugs out there, which means patients need to pay attention to them.

It gives us more options as patients because some of the drugs have been developed for brand new treatment categories, which means that proteasome inhibitors and IMiDs that we use and have been effective, it may be that one of the new treatments categories ‑‑ monoclonal antibodies, for example ‑‑ will be added to it and give us a more effective arsenal.

At the same time, these drugs have been approved for certain types of usage. All have been approved for patients who've had previous therapies. Some have been approved to be combined with other drugs.

That's one of the reasons we expect to hear a lot at ASH is trials are still going on with these drugs to expand those approvals, so that they become approved for newly diagnosed patients, or get approved in a maintenance role and such.

Patients need to keep on top of what the approvals mean to them, and I hope their doctor knows all about them as well.

Share this:

Recommended For You
FDA Approvals, News & UpdatesMultiple Myeloma
Blenrep, First BCMA Antibody, Receives FDA Approval for Relapsed or Refractory Multiple Myeloma
In August 2020, the FDA approved the first BCMA-directed antibody, Blenrep, for the treatment of adults with multiple myeloma that progressed after 4 or more previous therapies. This drug represents a new approach to the treatment of multiple myeloma.
Multiple Myeloma
CAR T-Cell Therapies Produce Durable Responses in Patients with Relapsed or Refractory Multiple Myeloma
By Chase Doyle
Cell-based therapy is becoming an attractive option for the treatment of patients with relapsed (coming back) or refractory (does not respond to therapy) multiple myeloma who have received many therapies before.
Multiple Myeloma
Velcade, Revlimid, and Dexamethasone Combination Remains Standard-of-Care First-Line Therapy for Patients with Multiple Myeloma
By Chase Doyle
In patients with newly diagnosed multiple myeloma, the use of the 3-drug combination of Kyprolis (carfilzomib), Revlimid (lenalidomide), and dexamethasone for first-line therapy does not improve outcomes compared with the 3-drug combination of Velcade (bortezomib), lenalidomide, and dexamethasone, which is the current standard of care for this patient population.
FDA Approvals, News & UpdatesMultiple Myeloma
FDA Approves Blenrep for Patients with Relapsed or Refractory Multiple Myeloma
On August 5, 2020, the FDA accelerated the approval of Blenrep (belantamab mafodotin-blmf; from GlaxoSmithKline), a B-cell maturation antigen (BCMA)-directed antibody and microtubule inhibitor conjugate, for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 previous therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
Last modified: October 5, 2017

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.